Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide

Shijun Ren, Zoltan A. Tokes, Csaba Csipke, Bingsen Zhou, Yun Yen, Eric J. Lien

研究成果: 雜誌貢獻文章同行評審

11 引文 斯高帕斯(Scopus)


The inhibitory activities of Schiff bases of hydroxysemicarbazide (HSC) against eight human and murine tumor cell lines and one non-cancer cell line were studied using MTS/PES microculture tetrazolium and methylene blue assays. Compounds 1 (1-[9-(10-methylanthryl)methylene]-4-HSC), 2 (1-[2-hydroxy-3,5-dibromobenzylidene]-4-HSC) and 3 (1-[2,3,4-trihydroxybenzylidene]-4-HSC), which have been shown to be active against murine leukemia L1210 cells in our laboratories, inhibited human leukemia CCRF-CEM cells with similar IC50s ranging from 2.7 to 7.0 μM. Of the compounds tested against attached tumor cell lines (B16, CHO, HT29, ZR75) at 50 μM concentration, compound 1 showed the strongest inhibition, followed by 4 (1-[2-(5-nitrothienyl)-methylene]-4-HSC), 2 and 5 (1-[2-hydroxy-3,5-diiodobenzylidene]-4-HSC) with more than 50% inhibition. The IC50s of compound 1 were found to range from 2.7 to 12 μM against the attached tumor cell lines examined. As compared with hydroxyurea, compound 1 had more favorable selectivity against tumor cells. Further more, compound 1 was found to have IC50s of 2.8 and 6.5 μM against hydroxyurea-resistant and gemcitabine-resistant KB cells, respectively, but had no cross-resistance with hydroxyurea and gemcitabine (two known ribonucleotide reductase inhibitors acting at different sites of the same enzyme). In conclusion, several Schiff bases of HSC showed inhibition of tumor cell growth at micromolar concentration and had no cross-resistance with hydroxyurea-resistant KB cells.

頁(從 - 到)3445-3451
期刊Anticancer Research
出版狀態已發佈 - 2001

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究


深入研究「Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide」主題。共同形成了獨特的指紋。